ADVA Biotechnology develops enabling technologies for cell therapy manufacturing. The company has developed ADVA X3, a robust, modular cell-manufacturing cGMP system based on a single-use end-to-end solution.

ADVA X3 enables autologous cell therapy manufacturing at the bedside, allowing optimization, tight quality assurance, improved availability, reduced time to market, and significant cost reduction. The automated platform is designed to enable autologous manufacturing of additional types of cells with a change in the disposable chamber, allowing efficiency and flexibility with a long pipeline of products.